Wilate Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Mechanism of Action
Wilate Indications
Indications
On-demand treatment and control of bleeding episodes in patients with von Willebrand disease (VWD) or hemophilia A. Perioperative management of bleeding in patients with VWD. Routine prophylaxis to reduce the frequency of bleeding episodes in patients with VMD or hemophilia A.
Wilate Dosage and Administration
Adults and Children
Give by IV injection at 2–4mL/min. VWD (<5yrs): contact manufacturer; (≥5yrs): Minor bleed: 20–40 IU/kg once, then 20–30 IU/kg every 12–24 hours as needed. Major bleed: 40–60 IU/kg once, then 20–40 IU/kg every 12–24 hours as needed. Surgery (give loading dose within 3hrs before); Minor: 30–60 IU/kg once, then 15–30 IU/kg (or half the loading dose) every 12–24 hours; Major: 40–60 IU/kg once, then 20–40 IU/kg (or half the loading dose) every 12–24 hours. Routine prophylaxis (≥6yrs): 20–40 IU/kg two or three times per week. Monitor and adjust according to VWF:RCo and FVIII activity, and location of bleed; usual treatment duration is 3 days (minor hemorrhage, minor surgery), 5–7 days (major hemorrhage), or ≥6 days (major surgery). Hemophilia A (<12yrs): contact manufacturer; (≥12yrs): Minor bleed: 30–40 IU/kg every 12–24 hours for ≥1 day. Moderate bleed: 30–40 IU/kg every 12–24 hours for ≥3–4 days. Major bleed: 35–50 IU/kg every 12–24 hours for ≥3–4 days. Life-threatening: 35–50 IU/kg every 8–24 hours until resolved. Routine prophylaxis: 20–40 IU/kg every 2–3 days. Monitor and adjust according to severity of deficiency/hemorrhage, desired FVIII level, presence of inhibitor. See full labeling.
Wilate Contraindications
Not Applicable
Wilate Boxed Warnings
Not Applicable
Wilate Warnings/Precautions
Warnings/Precautions
Wilate Pharmacokinetics
Absorption
Cmax (VWD): 76.8 ± 1.3 IU/dL in children; (hemophilia A): 113.82 ± 20.53 IU/dL in adults; 83.92 ± 9.40 IU/dL in adolescents.
Distribution
Volume of distribution at steady state (VWD): 0.8 ± 1.5 dL/kg in children; (hemophilia A): 0.53 ± 0.13 dL/kg in adults; 0.73 ± 0.13 in adolescents.
Elimination
Clearance rate (VWD): 0.1 ± 1.5 dL/h/kg in children; (hemophilia A): 0.035 ± 0.013 dL/h/kg in adults; 0.051 ± 0.008 dL/h/kg in adolescents. Half-life (VWD): 8.3 ± 1.7 hours in children; (hemophilia A): 10.64 ± 2.69 hours in adults;11.41 ± 1.93 hours in adolescents.
Wilate Interactions
Not Applicable
Wilate Adverse Reactions
Adverse Reactions
Wilate Clinical Trials
See Literature
Wilate Note
Not Applicable
Wilate Patient Counseling
See Literature
Images
